Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel.
Schutz FAB, Sirachainan E, Kuppusamy S, Hoa NTT, Dejthevaporn T, Bahadzor B, Toan VQ, Chansriwong P, Alip A, Hue NTM, Parinyanitikul N, Tan AL, Hoang VDK, Tienchaiananda P, Chinchapattanam SND, Garg A. Schutz FAB, et al. Among authors: tienchaiananda p. Ther Adv Med Oncol. 2021 Feb 23;13:1758835920985464. doi: 10.1177/1758835920985464. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33747148 Free PMC article. Review.
A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Tienchaiananda P, Nipondhkit W, Maneenil K, Sa-Nguansai S, Payapwattanawong S, Laohavinij S, Maneechavakajorn J. Tienchaiananda P, et al. Ann Palliat Med. 2019 Sep;8(4):372-380. doi: 10.21037/apm.2019.08.04. Epub 2019 Sep 2. Ann Palliat Med. 2019. PMID: 31500422 Free article. Clinical Trial.
Olanzapine: is it enough for CINV prevention?
Tienchaiananda P, Nipondhkit W, Prasongsook N. Tienchaiananda P, et al. Ann Palliat Med. 2020 Jul;9(4):2427-2429. doi: 10.21037/apm-20-1018. Epub 2020 May 18. Ann Palliat Med. 2020. PMID: 32434367 Free article. No abstract available.
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial.
Chen Y, Li WX, Wu JH, Chen GH, Yang CM, Lu H, Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Hong RX, Jiang KK, Zhong YY, Zhang G, Tienchaiananda P, Oikawa M, Yuan ZY, Chen QJ. Chen Y, et al. Among authors: tienchaiananda p. Breast Cancer (Dove Med Press). 2024 Apr 12;16:223-231. doi: 10.2147/BCTT.S447290. eCollection 2024. Breast Cancer (Dove Med Press). 2024. PMID: 38628818 Free PMC article. Clinical Trial.
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators. Powles T, et al. N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117. N Engl J Med. 2024. PMID: 38446675 Clinical Trial.